Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO), announced today it has successfully incorporated the use of High Resolution Melt (HRM) technology into its ICE COLD-PCR(TM) (ICP) kits, substantially improving its liquid biopsy testing cost and time efficiency.
Customers using Precipio's ICP for liquid biopsy may enjoy an additional reduction in their cost per specimen, potentially improving their margin by an estimated 25-50%, depending on the ratio of positive/negative cases).
This further strengthens Precipio's ICP platform as what we believe to be the industry's leading, most cost-effective technology for liquid biopsies.
The use of HRM as a screening tool enables laboratories to quickly and effectively rule out the patient samples that turn out negative for a genetic mutation in the region of interest. Obtaining that information through a simple and quick up-front step potentially eliminates the need to perform more complex and costly genetic mutation detection (e.g. next generation sequencing), significantly reducing the cost of testing and the wait time involved, from 7-10 days, to a matter of hours.
Much like ICP, HRM can be applied to any of the downstream technologies ICP works on, such as RT-PCR, Sanger, and or NGS (expected 2nd half of 2018).
"The incorporation of HRM into our kits further sets ICP apart from all other competitors. While competitors focus on large, expensive panels, not easily reimbursed, our low-cost, efficient, reimbursable and targeted panels can now yield a same-day result (for negative cases)," said Ilan Danieli, Precipio's CEO. "Our customer pipeline continues to grow as more laboratories realize the clinical and economic value that ICP brings them."
What is High Resolution Melt (HRM)
HRM is a targeted screening tool used for the detection of genetic mutations in DNA. This technique has three main advantages over alternative mutation detection technologies:
News 
Market Data 
Discover 
AI
